Reviva Pharmaceuticals RVPH Q1 2026 Earnings NarrowerthanExpected Loss Highlights Cost Discipline Amid PreRevenue Stage RVTY Q1 2026 Earnings EPS Surpasses Estimates Amid Flat Stock Reaction HOVR Q1 2026 Earnings EPS Misses Estimates Despite Stock Surge UFCS Q1 2026 Earnings Strong EPS Beat Reflects Improved Underwriting Performance SYPR Q3 2025 Earnings Return to Profitability with EPS of 002 ING Q1 2026 Earnings Earnings Beat Estimates as Shares Rise Over 27